Arena Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Arena Pharmaceuticals, Inc. (ARNA), a biopharmaceutical company founded in 1997 and headquartered in San Diego, California, develops small molecule drugs targeting G protein-coupled receptors for therapeutic applications in immuno-inflammatory, cardiovascular, and pain-related disorders. The company's pipeline features etrasimod, an oral selective sphingosine 1-phosphate receptor modulator in development for ulcerative colitis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata; ralinepag, an oral prostacyclin receptor agonist for pulmonary arterial hypertension; temanogrel, a selective 5-HT2A inverse agonist for microvascular obstruction and Raynaud's phenomenon in systemic sclerosis; olorinab, a cannabinoid receptor 2 agonist for visceral pain in gastrointestinal conditions including irritable bowel syndrome; and APD418, a beta-3 adrenergic receptor antagonist for acute heart failure. Previously marketed Belviq (lorcaserin) for obesity, which generated modest sales and was sold to Eisai in 2017 along with associated royalties. Arena operates primarily in the United States with select international partnerships, such as a 2017 development and commercialization alliance with Everest Medicines for ralinepag and etrasimod in Greater China, entitling Arena to milestone payments up to $224 million and royalties. In March 2022, Pfizer completed its $6.7 billion acquisition of Arena, integrating its pipeline into Pfizer's inflammation and immunology portfolio to accelerate clinical programs like the Phase 3 ELEVATE-UC trial for etrasimod, with Arena now operating as a wholly-owned subsidiary and its shares delisted from Nasdaq.
Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals
Pfizer Completes Acquisition of Arena Pharmaceuticals
7 Biotech Stocks With Key Catalysts in March
11 Marijuana Stocks on Fire to Close February
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
Top 3 weed stocks to put on your watch list this year
Pharma Giants Go After $10 Billion Market With RSV Drugs
Cannabis Watch: Pfizer's Arena Pharma deal may lead drug company to a cannabis-based treatment
Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?
Abivax: Potentially The Next Arena Pharmaceuticals, Most Ideal Big Pharma M&A Target In 2022
Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline
Does PFE, ARNA Deal Signal Robust Pharma M&A Activity in 2022?
Pfizer's acquisition of Arena "shows big pharma's interest in cannabinoid medicines"
Why Arena Pharmaceuticals Stock Skyrocketed 80% Today
SHAREHOLDER ALERT: WeissLaw LLP Investigates Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals up 90% after acquisition announcement
Pfizer stock heads toward record after $6.7 billion takeover of Arena; deal ‘makes strategic sense to us,' says analyst
ARNA Stock Alert: The Pfizer Deal That Has Arena Pharmaceuticals Rocketing Today
How Pfizer Is Getting Into Cannabis With $6.7B Arena Pharma Deal
Why Arena Pharmaceuticals Stock Is Soaring Today